SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery
SOHM (OTCID:SHMN) on November 6, 2025 released a technical white paper describing ABBIE, a Cas9-guided integrase platform that enables targeted donor-DNA integration without double-strand breaks or viral vectors. Using ABBIE, the team generated SKOV3-GYS1, an ovarian cancer cell line with stable overexpression of glycogen synthase 1 to support drug-discovery assays.
Key technical findings include non-viral, DSB-free integration, ~3× GYS1 protein levels versus parental SKOV3, >5× GYS1 catalytic activity, and whole-genome sequencing showing a single integration event in an intergenic locus. The company notes target-site variability and ongoing work to refine insertion precision. SOHM invites partnerships to apply ABBIE-engineered models for assay and screening development.
SOHM (OTCID:SHMN) il 6 novembre 2025 ha pubblicato un white paper tecnico che descrive ABBIE, una piattaforma di integrasi guidata da Cas9 che consente l'integrazione mirata di DNA donatore senza double-strand breaks né vettori virali. Utilizzando ABBIE, il team ha generato SKOV3-GYS1, una linea cellulare di cancro ovarico con sovraespressione stabile di glycogen synthase 1 per supportare saggi di scoperta di farmaci.
Tra i principali risultati tecnici figurano integrazione non virale, priva di DSB, circa 3× i livelli di proteina GYS1 rispetto al SKOV3 originale, 5× l'attività catalitica di GYS1, e un sequenziamento dell'intero genoma che mostra un unico evento di integrazione in una regione intergenica. L'azienda nota variabilità del sito bersaglio e lavora in corso per affinare la precisione dell'inserimento. SOHM invita a collaborazioni per applicare modelli ingegnerizzati con ABBIE a sviluppo di saggi e di screening.
SOHM (OTCID:SHMN) el 6 de noviembre de 2025 publicó un documento técnico que describe ABBIE, una plataforma de integrasa guiada por Cas9 que permite la integración dirigida de ADN donante sin rupturas de doble helice ni vectores virales. Usando ABBIE, el equipo generó SKOV3-GYS1, una línea celular de cáncer de ovario con sobreexpresión estable de glicógeno sintasa 1 para apoyar ensayos de descubrimiento de fármacos.
Los hallazgos técnicos clave incluyen integración no viral, sin DSB, ~3× niveles de proteína GYS1 frente al SKOV3 parental, 5× actividad catalítica de GYS1, y secuenciación del genoma completo que muestra un único evento de integración en una locus intergenico. La empresa señala variabilidad en los sitios objetivo y continúa trabajando para refinar la precisión de la inserción. SOHM invita a colaborar para aplicar modelos ABBIE-engineered a desarrollo de ensayos y cribado.
SOHM (OTCID:SHMN)는 2025년 11월 6일에 Cas9 가이드 인티그래이스 플랫폼인 ABBIE를 설명하는 기술 백서를 발표했습니다. 이는 더블 가닥 끊김이나 바이러스 벡터 없이 표적 donor-DNA 삽입을 가능하게 합니다. ABBIE를 사용하여 팀은 SKOV3-GYS1을 생성했으며, 글리코겐 신스이즈 1의 발현이 안정적으로 증가한 난소 암 세포주로 약물 발견 실험을 지원합니다.
주요 기술적 발견으로는 비바이럴, DSB-free 삽입, 부모형 SKOV3 대비 약 3×의 GYS1 단백질 레벨, 5×의 GYS1 촉매 활성, 그리고 전체 유전체 시퀀싱에서 간섭 없는 단일 삽입이 나타난 간선 외 영역(인트라게놈)에서의 삽입 발견이 있습니다. 회사는 표적 부위의 가변성과 삽입 정밀도 개선 작업이 계속 진행 중임을 언급합니다. SOHM은 ABBIE 공학 모델을 활용한 분석 및 스크리닝 개발 협력을 요청합니다.
SOHM (OTCID:SHMN) a publié le 6 novembre 2025 un livre blanc technique décrivant ABBIE, une plateforme d'intégrase guidée par Cas9 qui permet l'intégration ciblée d'ADN donneur sans cassures double brin ni vecteurs viraux. En utilisant ABBIE, l'équipe a généré SKOV3-GYS1, une lignée de cancer de l'ovaire à expression stable de glycogen synthase 1 pour soutenir les essais de découverte de médicaments.
Les résultats techniques clés incluent une intégration non virale, sans DSB, environ 3× les niveaux de protéine GYS1 par rapport au SKOV3 parental, 5× l'activité catalytique de GYS1, et un séquençage du génome entier montrant un seul événement d'intégration dans un locus intergénique. L'entreprise note une variabilité des sites cibles et des travaux en cours pour affiner la précision de l'insertion. SOHM invite des partenariats pour appliquer des modèles ABBIE-engineered à l'élaboration d'essais et de screening.
SOHM (OTCID:SHMN) veröffentlichte am 6. November 2025 ein technisches Whitepaper, das ABBIE beschreibt, eine Cas9-geleitete Integrase-Plattform, die eine zielgerichtete Integration von Donor-DNA ohne Doppelstrangbrüche oder virale Vektoren ermöglicht. Mit ABBIE erzeugte das Team SKOV3-GYS1, eine Eierstockkrebs-Zelllinie mit stabiler Überexpression von Glykogensynthase 1 zur Unterstützung von Wirkstoffentdeckungs-Assays.
Zu den wichtigsten technischen Erkenntnissen gehören nicht-virale, DSB-freie Integration, ca. 3× GYS1-Proteinniveau gegenüber dem elterlichen SKOV3, 5× die katalytische Aktivität von GYS1 und eine Ganzgenomsequenzierung, die einen einzigen Integrationsvorgang an einer intergenischen Stelle zeigt. Das Unternehmen verweist auf Variabilität der Zielstellen und laufende Arbeiten zur Feinabstimmung der Insertionsgenauigkeit. SOHM lädt zu Partnerschaften ein, um ABBIE-engineerte Modelle für Assay- und Screening-Entwicklung anzuwenden.
SOHM (OTCID:SHMN) في 6 نوفمبر 2025 أصدرت ورقة بيضاء تقنية تصف ABBIE، وهي منصة إنتيجراز مُرشَّدة بواسطة Cas9 تسمح بالتكامل المستهدف لـ DNA المانح دون كسر خيوط مزدوجة أو ناقلات فيروسية. باستخدام ABBIE، أنشأ الفريق SKOV3-GYS1، خط خلايا سرطان المبايض مع تعبير زائد مستقر لـ glycogen synthase 1 لدعم اختبارات اكتشاف الأدوية.
تشمل النتائج التقنية الرئيسية تكامل غير فيروسي خالٍ من DSB، نحو 3× مستويات بروتين GYS1 مقارنة بـ SKOV3 الأب، 5× النشاط التحفيزي لـ GYS1، وت Sequencing الجينوم الكامل يظهر حدث تكامل واحد في موضع بين جيني. وتشير الشركة إلى وجود تقلب في مواقع الهدف والعمل جارٍ لتحسين دقة الإدراج. تدعو SOHM إلى شراكات لتطبيق نماذج ABBIE-engineered في تطوير الاختبارات والفحص.
- Non-viral, DSB-free targeted integration platform
- GYS1 protein ~3× vs parental SKOV3
- GYS1 catalytic activity >5× vs parental SKOV3
- Single stable integration observed by whole-genome sequencing
- Established SKOV3-GYS1 cell line for GYS1 drug discovery
- Insertion coordinates can diverge from canonical CRISPR target, reducing precision
- Ongoing studies needed to refine target-selection rules and reproducibility
CHINO HILLS, CALIFORNIA / ACCESS Newswire / November 6, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to announced the release of a technical white paper describing ABBIE, a Cas9-guided integrase platform that enables donor-DNA integration without double-strand breaks or viral vectors. Using ABBIE, the team established SKOV3-GYS1, an ovarian cancer cell line with stable overexpression of glycogen synthase 1 (GYS1) to support drug-discovery applications focused on glycogen metabolism.
Highlights from the white paper
Non-viral, DSB-free integration: ABBIE employs a dCas9-integrase fusion to guide targeted, donor-DNA integration while avoiding double-strand breaks and viral delivery.
Functional overexpression achieved: In ABBIE-engineered cells, GYS1 protein levels were ~3× those of parental SKOV3 cells, and GYS1 catalytic activity exceeded 5× parental levels.
Genomic characterization: Following selection, bulk populations exhibited stable donor integration. Whole-genome sequencing of the highest-expressing clone revealed a single integration event at an intergenic locus.
Targeting note & ongoing work: While ABBIE is guide-directed, the exact insertion coordinates can diverge from the canonical CRISPR-Cas9 target. Ongoing studies are refining target-selection rules and determinants of integration site choice to further improve precision and reproducibility.
Research and development significance
GYS1 plays a central role in glycogen metabolism and has been implicated in tumor survival under stress conditions. The SKOV3-GYS1 line offers a robust in-vitro platform for mechanistic studies and for screening GYS1-targeting small molecules and other metabolic modulators. More broadly, ABBIE's non-viral, DSB-free approach may help expand knock-in strategies for cell-engineering and model development.
Partnership opportunities
SOHM welcomes strategic partnerships to accelerate assay development, screening campaigns, and platform optimization using ABBIE-engineered models. Interested parties are invited to contact SOHM.
White paper: Articles and Publications - SOHM Inc.
https://sohm.com/abbie-and-the-future-of-cancer-research/
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What is ABBIE reported by SOHM (SHMN) on November 6, 2025?
How much did GYS1 expression increase in the SKOV3-GYS1 line created with ABBIE?
Did SOHM confirm stable genomic insertion for ABBIE-engineered cells?
Are there precision or reproducibility limitations with ABBIE noted by SOHM?
How can partners engage with SOHM regarding ABBIE and SKOV3-GYS1?
